BioSig Technologies Inc drew an ‘Outperform’ rating from Noble Capital, which noted that "stronger commercialization efforts” are underway for the company’s PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems after the first quarter. In a note to clients, Noble Capital analysts observed that BioSig recorded no PURE EP unit sales during the quarter, which was “below our expectations of three units”. However, they felt that BioSig still made great strides on multiple fronts as it accelerates commercial momentum for developing a national-installed base of its PURE EP systems. “The company received strong signals from facilities, but contracts were not signed by the end of the quarter. We expect agreements in the second quarter,” said analysts. “Total expenses, reduced by overhead reduction, ran higher than our expected levels as the company added back staff as part of its commercial buildout and official June 1 rollout,” they added.
Biocept Inc posted first-quarter results that saw its revenue jump 12% year-over-year on the back of its RT-PCR coronavirus (COVID-19) testing services. For the period ended March 31, 2022, the San Diego, California-based provider of molecular diagnostic assays, products, and services, reported revenue of $19.9 million, compared to $17.8 million in 1Q 2021. During the quarter, Biocept said it earned $18.6 million in RT-PCR COVID-19 test revenue, $1.3 million in oncology test revenue, $38,000 in development services test revenue and nothing for distributed products, Target Selector RUO kits and CEE-Sure blood collection tubes. The company had collected $16.8 million in RT-PCR COVID-19 test revenue and $2.5 million in oncology test revenue in 1Q 2021. Biocept accessioned 153,056 commercial samples during the quarter, compared with 141,340 commercial samples during the comparable quarter a year earlier.
Water Tower Research LLC said it has published an update note on EVmo Inc which can be viewed via the following link.
Starton Therapeutics Inc revealed that the Independent Data Monitoring Committee has recommended advancement to the third and final dose, where healthy subjects will receive the highest strength of STAR-LLD, a continuous delivery lenalidomide infusion, after reviewing the safety data from the first two cohorts in totality. The Paramus, New Jersey-based clinical-stage biotechnology company said in the ongoing Phase 1 STAR-LLD clinical trial, eight healthy subjects in the first two cohorts received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24-hour washout period. “The Phase 1 study evaluated STAR-LLD bioavailability, safety, and pharmacokinetics,” Starton chief medical officer Jamie Oliver said in a statement. “Progressing to the final dosing interval marks a major milestone in our development program; this study has established the compatibility and utility of the continuous infusion device with our subcutaneous formulation.”
TraceSafe Inc has said product innovation and repeat customers helped the company achieve a record year in 2021, with annual revenue of US$13 million, a 261% increase over the previous year. The global leader in Internet of Things (IoT) platforms for large-scale industrial and enterprise operations said the fourth quarter “sealed what was our most exciting year in performance and growth” with revenue up 28% year-over-year at US$2.3 million. “We achieved various sales milestones, expanded globally and renewed contracts with prestigious customers with continuous product innovation," said TraceSafe CEO Wayne Lloyd in a statement. "Our consistent ability to deliver with speed and scale kept bringing some of our biggest customers back across governments and enterprises.”
Irwin Naturals Inc said it has completed the acquisition of KHC Capital Group, LLC. which owns a chain of five ketamine treatment clinics in Florida and has an additional partnership contract with an affiliate clinic in Mexico. "Our roll-up strategy of clinics is highly accretive, enabling us to fuel rapid growth of revenues and profitability. With six clinics under our belt, a pipeline of over 100 targets in our M&A pipeline, and strong demand for these services, we have made the first meaningful strides towards executing on our vision,” the company's CEO, Klee Irwin, said in a statement. "This is important because, as a psychedelic, ketamine is a stunningly effective treatment1 for many mental health disorders. However, some Americans are not clear on its effectiveness. With nearly 80% of US households familiar with the trusted Irwin brand, it will be the welcome face of a familiar friend in a crowd of strangers - making this lifesaving solution a bit less intimidating to those in need," he added.
Potent Ventures Inc said it has closed a non-brokered private placement issuing a total of 8,914,999 units at a price of 3 cents per unit for aggregate proceeds of $365,000. The company said it intends to use the proceeds raised from the offering for general capital purposes. Each unit in the placement comprised one common share and one a transferrable share purchase warrant of the company. Each warrant will entitle the holder to purchase an additional share at a price of 5 cents per for a two-year period after the closing date. All the securities issued are subject to a four-month-and-a-day hold period from the date of issuance. Insiders of the company purchased an aggregate of 1 million units in the offering.
Trees Corporation said the board of directors of the company has approved the granting of options to purchase up to 6,190,696 common shares in the capital of the company to certain employees and consultants of the company, and the award of an aggregate of 17,741,607 restricted share units to certain officers and directors of the company. The options are exercisable at a price of $0.03 per share for a period of five years from the date of issuance.
Thunderbird Entertainment Group Inc said its board of directors has authorized the grant of an aggregate of 200,000 incentive stock options in accordance with the terms of the company's stock option plan to employees at the executive level. The options are exercisable at a price of $3.50 per share and have a seven-year term, subject to vesting provisions.
Deep-South Resources Inc Chairman John Akwenye died over the weekend at the age of 71, the company announced. He will not be immediately replaced as chairman. “This is an important loss,” CEO Pierre Leveille said in a statement. “Mr. Akwenye was a hard worker and highly dedicated to Deep-South. We lose a great person who was honest, loyal, resilient and very generous. His profound faith has helped many people to overcome difficult periods. On a personal side, I lose a great friend.”
Goldshore Resources Inc said the TSX Venture Exchange has accepted for filing documentation with respect to its non-brokered private placement announced on May 18, 2022, which will see the issue of 1 million shares at a purchase price: of 50 cents per share, together with 500,000 share purchase warrants with an exercise price of 75 cents for a two-year period with one placee.
Naturally Splendid Enterprises Ltd said the TSX Venture Exchange has consented to the extension in the expiry date of 26,321,016 warrants with an original expiry date of June 4, 2022, to a new expiry date of June 4, 2023, at an unchanged exercise price of 5.5 cents. The warrants were issued under a private placement of 42,857,159 shares with 42,857,159 share purchase warrants attached, which was accepted for filing by the exchange effective June 9, 2020.